Ceapro

Ceapro today provided an update on its ongoing collaboration with McMaster University to develop an inhalable therapeutic for COVID-19. The project, entitled PGX-processed yeast beta-glucans as an inhalable immunomodulating therapeutic for COVID-19 patients, jointly funded by Mitacs and Ceapro, is under the leadership of Dr. Kjetil Ask, a pulmonary fibrosis expert, and Dr. Todd Hoare respectively from departments of Medicine and Chemical Engineering at McMaster University. ...To assess the potential of PGX-processed yeast beta-glucan (PGX-YBG) in practical application for COVID-19, the project was designed with four aims or milestones. The first milestone was to optimize the size and morphology of the best PGX-YBG for immunomodulation while the second milestone was to examine tolerability and safety of inhaled PGX-YBG in naïve animal models. The first milestone of the project was fully achieved, and the second milestone is near completion. Learn more: See more

Ceapro today announced that positive results demonstrating the anti-inflammatory and immunomodulating properties of avenanthramides have been accepted for publication in the international, peer-reviewed Journal of the International Society of Sports Nutrition. The article titled Avenanthramide supplementation reduces exercise-induced inflammation in young men and women, is now available online. The study was co-funded by Pepsi Co and Ceapro Inc. Learn more: https://bit.ly/2Ppxvfa

Ceapro Announces Results of 2020 Shareholders’ Meeting

Ceapro today announced that results from a collaborative project with McMaster University researchers have been accepted for publication in the international, peer-reviewed journal, Acta Biomaterialia in an article titled Drug-Impregnated, Pressurized Gas Expanded Liquid-Processed Alginate Hydrogel Scaffolds for Accelerated Burn Wound Healing. The results from the successful drug-impregnation of PGX liquid processed alginate hydrogel scaffolds further bolsters Ceapro’s efforts to develop innovative delivery systems composed of new chemical complexes. Fore more information: https://bit.ly/3hrBEMt

Ceapro today announced that Gilles Gagnon, M. Sc., MBA, President and CEO of Ceapro will present at the Virtual Investor Fireside Chat Series on Wednesday, June 17, 2020 at 10:00 AM ET. A live video webcast of the fireside chat will be available on the IR Calendar page of the Investors section of the Company’s website. Immediately following the fireside chat, management will participate in an interactive Q&A session with interested parties, allowing participants to type in questions and receive live responses. A webcast replay will be available two hours following the live presentation and will be accessible for one year. For more information: https://bit.ly/2BGIeOL

Ceapro Inc. Reports 2020 First Quarter Financial Results and Highlights https://bit.ly/2ZJDFNG